These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12565959)

  • 1. 1,4-Diazepane-2-ones as novel inhibitors of LFA-1.
    Wattanasin S; Albert R; Ehrhardt C; Roche D; Sabio M; Hommel U; Welzenbach K; Weitz-Schmidt G
    Bioorg Med Chem Lett; 2003 Feb; 13(3):499-502. PubMed ID: 12565959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors.
    Lin EY; Guckian KM; Silvian L; Chin D; Boriack-Sjodin PA; van Vlijmen H; Friedman JE; Scott DM
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5245-8. PubMed ID: 18783948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of a series of meta aniline-based LFA-1 ICAM inhibitors.
    Guckian KM; Lin EY; Silvian L; Friedman JE; Chin D; Scott DM
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5249-51. PubMed ID: 18778938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1.
    Wattanasin S; Kallen J; Myers S; Guo Q; Sabio M; Ehrhardt C; Albert R; Hommel U; Weckbecker G; Welzenbach K; Weitz-Schmidt G
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1217-20. PubMed ID: 15686945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold.
    Potin D; Launay M; Nicolai E; Fabreguette M; Malabre P; Caussade F; Besse D; Skala S; Stetsko DK; Todderud G; Beno BR; Cheney DL; Chang CJ; Sheriff S; Hollenbaugh DL; Barrish JC; Iwanowicz EJ; Suchard SJ; Dhar TG
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1161-4. PubMed ID: 15686933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship.
    Burdick DJ; Paris K; Weese K; Stanley M; Beresini M; Clark K; McDowell RS; Marsters JC; Gadek TR
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1015-8. PubMed ID: 12643901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: structure-activity relationship of the benzoyl moiety.
    Burdick DJ; Marsters JC; Aliagas-Martin I; Stanley M; Beresini M; Clark K; McDowell RS; Gadek TR
    Bioorg Med Chem Lett; 2004 May; 14(9):2055-9. PubMed ID: 15080978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists.
    Link JT; Sorensen B; Liu G; Pei Z; Reilly EB; Leitza S; Okasinski G
    Bioorg Med Chem Lett; 2001 Apr; 11(8):973-6. PubMed ID: 11327603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino-substituted heterocycles as isosteres of trans-cinnamides: design and synthesis of heterocyclic biaryl sulfides as potent antagonists of LFA-1/ICAM-1 binding.
    Wang GT; Wang S; Gentles R; Sowin T; Leitza S; Reilly EB; von Geldern TW
    Bioorg Med Chem Lett; 2005 Jan; 15(1):195-201. PubMed ID: 15582439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold.
    Dodd DS; Sheriff S; Chang CJ; Stetsko DK; Phillips LM; Zhang Y; Launay M; Potin D; Vaccaro W; Poss MA; McKinnon M; Barrish JC; Suchard SJ; Murali Dhar TG
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1908-11. PubMed ID: 17291752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin-derived 1,3-oxazinan-2-ones as submicromolar inhibitors of LFA-1/ICAM-1 interaction: stabilization of the metabolically labile vanillyl side chain.
    Ullrich T; Baumann K; Welzenbach K; Schmutz S; Camenisch G; Meingassner JG; Weitz-Schmidt G
    Bioorg Med Chem Lett; 2004 May; 14(10):2483-7. PubMed ID: 15109637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.
    Liu G; Huth JR; Olejniczak ET; Mendoza R; DeVries P; Leitza S; Reilly EB; Okasinski GF; Fesik SW; von Geldern TW
    J Med Chem; 2001 Apr; 44(8):1202-10. PubMed ID: 11312920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and functional evaluation of leukocyte function associated antigen-1 antagonists in early and late stages of cancer development.
    San Sebastián E; Zimmerman T; Zubia A; Vara Y; Martin E; Sirockin F; Dejaegere A; Stote RH; Lopez X; Pantoja-Uceda D; Valcárcel M; Mendoza L; Vidal-Vanaclocha F; Cossío FP; Blanco FJ
    J Med Chem; 2013 Feb; 56(3):735-47. PubMed ID: 23339734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1.
    Huang L; Shimaoka M; Rondon IJ; Roy I; Chang Q; Po M; Dransfield DT; Ladner RC; Edge AS; Salas A; Wood CR; Springer TA; Cohen EH
    J Leukoc Biol; 2006 Oct; 80(4):905-14. PubMed ID: 16888085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
    Zhong M; Shen W; Barr KJ; Arbitrario JP; Arkin MR; Bui M; Chen T; Cunningham BC; Evanchik MJ; Hanan EJ; Hoch U; Huen K; Hyde J; Kumer JL; Lac T; Lawrence CE; Martell JR; Oslob JD; Paulvannan K; Prabhu S; Silverman JA; Wright J; Yu CH; Zhu J; Flanagan WM
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5269-73. PubMed ID: 20655213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adxanthromycins A and B, new inhibitors of ICAM-1/LFA-1 mediated cell adhesion molecule from Streptomyces sp. NA-148. I. Taxonomy, production, isolation and biological activities.
    Nakano T; Koiwa T; Takahashi S; Nakagawa A
    J Antibiot (Tokyo); 2000 Jan; 53(1):12-8. PubMed ID: 10724002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual screening leads to the discovery of an effective antagonist of lymphocyte function-associated antigen-1.
    Shoda M; Harada T; Yano K; Stahura FL; Himeno T; Shiojiri S; Kogami Y; Kouji H; Bajorath J
    ChemMedChem; 2007 Apr; 2(4):515-21. PubMed ID: 17340656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of molecular interactions between intercellular adhesion molecule-1 and leukocyte function- associated antigen-1.
    Woska JR; Morelock MM; Jeanfavre DD; Bormann BJ
    J Immunol; 1996 Jun; 156(12):4680-5. PubMed ID: 8648112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry.
    Crump MP; Ceska TA; Spyracopoulos L; Henry A; Archibald SC; Alexander R; Taylor RJ; Findlow SC; O'Connell J; Robinson MK; Shock A
    Biochemistry; 2004 Mar; 43(9):2394-404. PubMed ID: 14992576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein--protein interaction.
    Last-Barney K; Davidson W; Cardozo M; Frye LL; Grygon CA; Hopkins JL; Jeanfavre DD; Pav S; Qian C; Stevenson JM; Tong L; Zindell R; Kelly TA
    J Am Chem Soc; 2001 Jun; 123(24):5643-50. PubMed ID: 11403595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.